Expert Interview
A Second Look: Examining the potential of Alpine Immune Sciences' povetacicept in treating autoimmune glomerulonephritis
Ticker(s): ALPNInstitution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 8-10 patients with CKD associated pruritus, and 6 patients with C3 glomerulopathy.
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
Roughly how many patients with autoimmune glomerulonephritis do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for povetacicept?
Added By: ben_adminThere are a number of BAFF and/or APRIL inhibitors for IgAN (and for glomerulonephritis) -- do dual BAFF/APRIL inhibitors have any advantages over single-pathway BAFF or APRIL inhibitors, especially in IgAN? Thank you.
What BAFF/APRIL inhibitor(s) do you expect to emerge as leading treatment(s) for IgAN?
Added By: userab1cba17What additional data should povetacicept, or any BAFF/APRIL inhibitor in IgAN, generate to differentiate themselves from the BAFF/APRIL inhibitor in IgAN competitive set, in addition to UPCR and eGFR data?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
